Is bortezomib an effective treatment for indolent or mantle-cell non-Hodgkin's lymphoma?
This research output was recommended by a member of Faculty Opinions.
Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Overview of attention for article published in Journal of Clinical Oncology, December 2004
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (95th percentile)
-
High Attention Score compared to outputs of the same age and source (81st percentile)
Mentioned by
- policy
- 1 policy source
- patent
- 3 patents
- wikipedia
- 5 Wikipedia pages
- f1000
- 1 research highlight platform
- guideline
- 1 clinical guideline source
Readers on
- mendeley
- 93 Mendeley